IP Library Granted Patent US 8,591,910
Granted Patent B2
US 8,591,910 · App. 13/543,718 · Granted Nov 26, 2013

Chemically programmable immunity

Inventor: Kary B. Mullis (Corona Del Mar, CA)
Assignee: Altermune Technologies LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,591,910
App. No.
13/543,718
Granted
Nov 26, 2013
Kind
B2
Abstract

The present invention is related to methods and compositions that are capable of immediately immunizing a human or animal against any molecule or compound. The present invention comprises an immunity linker molecule with at least two sites; (1) a first binding site that binds to an immune system molecule in a human or animal that has been preimmunized against the first binding site, and (2) one or more second binding sites that bind specifically to a desired compound or molecule. The first binding site and the second binding site(s) are linked by a linker portion of the molecule.

Claims (20)

1. An immune-diverting composition comprising an immunity linker molecule comprising

a first binding site that when administered to an individual is capable of binding to an antibody produced from a pre-existing immunity within the individual specific for a first compound or molecule, and

a second binding site comprising a nucleic acid aptamer or a modified nucleic acid aptamer that is capable of binding to a target, wherein the first compound or molecule and the target are not the same.

2. The immune-diverting composition of claim 1 , wherein the composition comprises an amount of the immunity linker molecule effective to provide substantially immediate immunity to the target.

3. The immune-diverting composition of claim 1 , wherein the pre-existing immunity is induced by an immunizing molecule and optionally an adjuvant or a booster.

4. The immune-diverting composition of claim 1 , wherein the immunity linker molecule comprises more than one second binding site.

5. The immune-diverting composition of claim 4 , wherein the binding sites differ in specificity for targets.

6. The immune-diverting composition of claim 1 , wherein the aptamer comprises a modified nucleic acid aptamer, and wherein the modified nucleic acid comprises 2′-fluoro or 2′-amino-2′deoxypyrimidine.

7. The immune-diverting composition of claim 1 further comprising a linking portion linking the first and second binding sites.

8. The immune-diverting composition of claim 7 , wherein the linking portion comprises a rigid or flexible spacer.

9. The immune-diverting composition of claim 8 , wherein the spacer is double stranded nucleic acid.

10. The immune-diverting composition of claim 1 , wherein the immunity linker further comprises a protein, a peptide, a nucleic acid, or a combination thereof.

11. The immune-diverting composition of claim 1 , wherein the target comprises a microorganism, a pathogen, a toxic substance, or a drug.

12. The immune-diverting composition of claim 11 , wherein the microorganism is a bacterium, a virus, or a fungus.

13. The immune-diverting composition of claim 1 , wherein the target comprises anthrax or a dengue virus.

14. The immune-diverting composition of claim 1 , wherein the individual is unable to mount an effective immune response to the target compound or molecule prior to administration of the composition.

15. The immune-diverting composition of claim 1 , wherein the composition is in a form suitable for at least one administration mode selected from the group consisting of intravenous administration, intramuscular administration, subcutaneous administration, oral administration, and mucosal administration.

16. A method of establishing substantially immediate immunity to a target in an individual comprising, wherein the method comprises administering to the individual an effective amount of the immune-diverting composition of claim 1 .

17. The method of claim 16 , wherein the individual is unable to mount an effective immune response to the target prior to the administering step.

18. The method of claim 16 , wherein the immunity to the target is a cellular or humoral immunity.

Continuity (6)
Continuation 12336746 · Dec 17, 2008
Continuation 11606564 · Nov 30, 2006
Continuation 10178046 · Jun 21, 2002
Continuation PCTUS0035179 · Dec 21, 2000
Provisional Application 60171707 · Dec 22, 1999
Related Publication 20120276136A1 · Nov 1, 2012